Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics, Inc. (HOWL) has agreed to merge Wave Atlantis Merger Sub, Inc. into Ambros Therapeutics, Inc.; Ambros would survive as Werewolf’s wholly owned subsidiary, and Werewolf would change its name to Ambros Therapeutics, Inc. Closing requires stockholder approvals, Nasdaq listing approval and cash proceeds from the Concurrent PIPE Financing of not less than $100.0 million (less applicable expenses). Investors have agreed to purchase Werewolf common stock and pre-funded warrants immediately before the Effective Time for an aggregate purchase price of $150.0 million. Estimated fully diluted ownership is 72.0% for Ambros holders, 21.6% for PIPE investors and 6.4% for pre-merger Werewolf holders outside the PIPE.
Werewolf expects to distribute one contingent value right (CVR) per outstanding share to holders of record before the Effective Time. CVRs provide a pro rata share of 100% of net proceeds actually received from monetizing WTX-124, WTX-330 and related assets through the third anniversary of Closing; amounts below $1,000,000 in an annual payment period carry forward, with any payment at the end of the CVR Period made regardless of whether the threshold is met. The combined company intends to focus primarily on neridronate and evaluate whether to advance or partner the Werewolf programs.
Werewolf Therapeutics, Inc. (HOWL) has filed a Form S-4 to register shares for a stock-for-stock merger with privately held Ambros Therapeutics, Inc. Ambros will merge into a Werewolf subsidiary, becoming a wholly owned unit, and Werewolf will be renamed “Ambros Therapeutics, Inc.” The deal is structured to qualify as a tax-free reorganization for U.S. federal income tax purposes and is expected to be accounted for as a reverse recapitalization, with Ambros treated as the accounting acquirer.
Immediately before closing, Ambros preferred stock converts into Ambros common; at closing, each Ambros common share will receive Werewolf common shares based on an Exchange Ratio, with certain large Ambros holders able to elect pre-funded warrants instead of shares above a 9.99% ownership cap. Concurrently, outside investors have agreed to invest $150.0 million in Werewolf common stock and pre-funded warrants in a PIPE financing. Werewolf will also distribute one contingent value right (CVR) per existing Werewolf share, giving holders contractual rights to 100% of defined Net Proceeds from dispositions of Werewolf’s legacy INDUKINE assets over a three-year period, subject to a $1,000,000 annual threshold mechanism.
Werewolf Therapeutics, Inc. (HOWL) reports that German private investor Peter Moll has filed a Schedule 13G disclosing a passive stake in the company’s common stock.
Moll beneficially owns 2,537,138 shares of Werewolf Therapeutics common stock, representing 5.2% of the outstanding class. He reports sole voting and sole dispositive power over all of these shares, with no shared voting or dispositive power. The filing describes him as a private investor and German citizen.
Werewolf Therapeutics, Inc. (HOWL) agreed to merge Ambros Therapeutics, Inc. into a wholly owned subsidiary, with the deal structured as a tax-free reorganization. Ambros stockholders will receive Werewolf common stock based on an exchange ratio, with the option to receive Merger Pre-Funded Warrants above a Beneficial Ownership Limitation.
Based on pro forma assumptions, legacy Werewolf equityholders (excluding PIPE participants) are expected to own 6.8% of the combined company, Ambros stockholders 71.7%, and PIPE investors 21.5%, reflecting implied valuations of $47.5 million for Werewolf and $500.0 million for Ambros. Concurrently, Werewolf entered into a $150.0 million private placement of common stock and PIPE pre-funded warrants, which must deliver at least $100.0 million in net cash proceeds at closing.
Werewolf will also issue one non-transferable contingent value right (CVR) per outstanding Werewolf share, entitling holders to potential cash payments tied to monetization of legacy INDUKINE programs WTX-124 and WTX-330, with no assurance of any payment. The merger requires stockholder approvals, Nasdaq listing and registration effectiveness, and that Werewolf Net Cash be greater than zero; customary termination fees of $20.0 million (Ambros) and $1.9 million (Werewolf) may apply in specified deal-failure scenarios.
Werewolf Therapeutics, Inc. (HOWL) entered into a definitive all‑stock merger agreement to combine with Ambros Therapeutics, with Ambros becoming a wholly owned subsidiary and the combined company expected to operate as Ambros Therapeutics and trade on Nasdaq as “AMBX.” Ambros stockholders will receive Werewolf common stock or pre‑funded warrants based on an exchange ratio reflecting an implied $500.0 million valuation for Ambros and $47.5 million for Werewolf.
On a fully diluted, treasury‑stock basis, pre‑merger Werewolf holders (excluding PIPE participants) are expected to own 6.8% of the combined company, pre‑merger Ambros stockholders 71.7%, and PIPE investors 21.5%, subject to adjustments including Werewolf net cash. Concurrently, Werewolf agreed to a $150.0 million private placement of common stock and PIPE pre‑funded warrants, with proceeds expected to fund Ambros’s pivotal CRPS‑RISE Phase 3 trial of neridronate and a planned NDA submission, providing cash runway into the first half of 2029. Existing Werewolf holders will receive one non‑transferable contingent value right per share tied to potential monetization of Werewolf’s legacy INDUKINE assets.
Werewolf Therapeutics, Inc. (HOWL) entered into an asset purchase agreement with EMD Serono Research & Development Institute Inc. on August 14, 2026, selling pre-clinical technology comprising its INDUCER platform and its INDUKINE platform (excluding the WTX-124 and WTX-330 clinical development programs) as the Transferred Assets. Werewolf retains all rights needed to continue developing its WTX-124 and WTX-330 clinical programs.
As consideration, EMD agreed to pay Werewolf upfront cash of $28.0 million plus an additional $5.0 million upon completion of the technology transfer. The parties provided customary representations, warranties, indemnities and a non-competition covenant under which Werewolf will not exploit certain compounds directed to the same tumor targets as any Transferred Compound for 24 months after closing, subject to change-of-control exceptions. Concurrently, EMD granted Werewolf an exclusive license to certain Transferred Assets patents necessary to conduct clinical development for WTX-124 and WTX-330, and additional license rights to support Werewolf’s existing collaboration arrangements with Harpoon Therapeutics, Inc. and Jazz Pharmaceuticals Ireland Limited.
Werewolf Therapeutics reported $21.0 million collaboration revenue in the second quarter of 2026 from selling its IFNα 898 Program to Jazz Pharmaceuticals, producing quarterly net income of $3.7 million after a prior-year loss. For the first half of 2026, the company still recorded a net loss of $9.9 million as R&D fell to $14.3 million and G&A rose to $12.8 million, reflecting a sharp pullback in development spending and higher advisory and legal costs tied to a strategic review.
Werewolf ended June 30, 2026 with $22.0 million in cash and cash equivalents and has fully repaid its $30.0 million K2 HealthVentures term loan via a $31.4 million payment, eliminating secured debt but triggering a $3.4 million extinguishment loss. Management discloses “substantial doubt” about the ability to continue as a going concern for at least twelve months and is exploring strategic alternatives, including a sale or partnerships, while executing a 2026 restructuring with major workforce reductions and an expected $6.5 million in total restructuring costs. Lead oncology programs WTX-124 and WTX-330 remain in early-stage trials targeted to complete in the fourth quarter of 2026, but further development will require additional funding or partners.
Werewolf Therapeutics, Inc. reported second quarter 2026 results highlighted by a shift to profitability and a major asset transaction. The company entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited for its JZP898 program and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC. These transactions included a $21.0 million payment to Werewolf and support ongoing evaluation of strategic alternatives with financial advisor Piper Sandler.
For the quarter ended June 30, 2026, collaboration revenue was $21.0 million, research and development expenses were $6.2 million versus $13.1 million a year earlier, and general and administrative expenses were $7.7 million versus $4.4 million. Net income was $3.7 million, compared with a net loss of $18.0 million in the prior-year period. As of June 30, 2026, cash and cash equivalents were $22.0 million, compared with $46.5 million as of March 31, 2026, and management expects existing cash to fund operations into the second quarter of 2027 while advancing INDUKINE and INDUCER pipeline programs, including WTX-124 and WTX-330.
Werewolf Therapeutics director Luke Evnin reported indirect open-market sales of 143,199 shares of Common Stock over two days. On July 6, 2026, entities associated with him sold 35,770 shares at a weighted average price of $0.32 per share. On July 7, 2026, they sold a further 107,429 shares at a weighted average price of $0.31 per share.
The trades were executed by multiple MPM-affiliated investment entities and carried out under a pre-established Rule 10b5-1 trading plan dated March 26, 2026. Following these transactions, those entities reported holding no shares of Werewolf Therapeutics.